Abstract: Provided are a piperidine derivative compound, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for the prevention or treatment of diseases related to autotaxin activity, comprising same as an active ingredient, in which the piperidine derivative compound exhibits excellent inhibitory activity against autotaxin, and thus can be effectively used in the treatment and prevention of diseases related to autotaxin inhibition, such as fibrotic diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, metabolic diseases, cancer and cancer metastasis, ocular diseases, cholestatic form and other forms of chronic pruritus, and acute or chronic organ transplant rejection.

Abstract: Provided are a piperidine derivative compound, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for the prevention or treatment of diseases related to autotaxin activity, comprising same as an active ingredient, in which the piperidine derivative compound exhibits excellent inhibitory activity against autotaxin, and thus can be effectively used in the treatment and prevention of diseases related to autotaxin inhibition, such as fibrotic diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, metabolic diseases, cancer and cancer metastasis, ocular diseases, cholestatic form and other forms of chronic pruritus, and acute or chronic organ transplant rejection.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating inflammatory bowel disease acting as a functional antagonist for S1PR1 and S1PR4 of S1P receptors, and more specifically, to a pharmaceutical composition including, as an active ingredient, a sphingolipid compound which does not cause cardiovascular side effects by acting as a functional antagonist for S1PR1 and S1PR4 and has an effect of preventing or treating inflammatory bowel disease.

Abstract: Disclosed are a tandem catalyst for synthesizing methyl acetate from carbon dioxide, a method for preparing the same, and a method for preparing methyl acetate using the same. The tandem catalyst of the present invention includes a first catalyst having a core-shell structure including a composite metal oxide core and a silica shell surrounding a surface of the composite metal oxide core, and a second catalyst including nano-ferrierite (N-FER) zeolite.

Abstract: The present invention relates to a method for evaluating an efficacy of an anticancer drug or an anticancer drug candidate, comprising the step of treating a mixture of cancer organoids and immune cells with the anticancer drug or the anticancer drug candidate. In addition, it relates to the anticancer drug efficacy evaluation system or anticancer drug screening system comprising cancer organoids and immune cells. The mixture of cancer organoids and immune cells according to the present invention is mixed in a specific ratio, and accordingly can similarly reproduce a tumor microenvironment in which cancer cells exist in the body. Therefore, it can make it possible to accurately predict the efficacy of the drug when administered to a subject.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating alopecia areata acting as a functional antagonist for SIP receptor's subtypes S1PR1 and S1PR4, and more particularly, relates to a pharmaceutical composition containing as an active ingredient a sphingolipid compound acting as a functional antagonist for S1PR1 and S1PR4, does not cause cardiovascular side effects, and is effective in preventing or treating alopecia areata.

Abstract: Disclosed are a tandem catalyst for synthesizing methyl acetate from carbon dioxide, a method for preparing the same, and a method for preparing methyl acetate using the same. The tandem catalyst of the present invention includes a first catalyst having a core-shell structure including a composite metal oxide core and a silica shell surrounding a surface of the composite metal oxide core, and a second catalyst including nano-ferrierite (N-FER) zeolite.

Abstract: A semiconductor device includes: a semiconductor device, comprising: a bit line structure including a bit line contact plug, a bit line, and a bit line hard mask that are sequentially stacked over a substrate; a storage node contact plug that is spaced apart from the bit line structure; a conformal spacer that is positioned between the bit line and the storage node contact plug and includes a low-k material; and a seed liner that is positioned between the conformal spacer and the bit line and thinner than the conformal spacer.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating alopecia areata acting as a functional antagonist for S1P receptor's subtypes S1PR1 and S1PR4, and more particularly, relates to a pharmaceutical composition containing as an active ingredient a sphingolipid compound acting as a functional antagonist for S1PR1 and S1PR4, does not cause cardiovascular side effects, and is effective in preventing or treating alopecia areata.

Abstract: The present disclosure relates to a 1,4-cyclohexanedimethanol (CHDM) composition and a purification method of the same. More specifically, it relates to a 1,4-cyclohexanedimethanol composition having a high purity due to a low by-product content and a high trans isomer ratio, and a method for purifying the same.

Abstract: Provided is an isomerization method of cyclohexane dicarboxylic acid using zirconia or titania as an isomerization catalyst.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating inflammatory bowel disease acting as a functional antagonist for S1PR1 and S1PR4 of S1P receptors, and more specifically, to a pharmaceutical composition including, as an active ingredient, a sphingolipid compound which does not cause cardiovascular side effects by acting as a functional antagonist for S1PR1 and S1PR4 and has an effect of preventing or treating inflammatory bowel disease.

Abstract: A semiconductor device includes: a semiconductor device, comprising: a bit line structure including a bit line contact plug, a bit line, and a bit line hard mask that are sequentially stacked over a substrate; a storage node contact plug that is spaced apart from the bit line structure; a conformal spacer that is positioned between the bit line and the storage node contact plug and includes a low-k material; and a seed liner that is positioned between the conformal spacer and the bit line and thinner than the conformal spacer.

Abstract: Provided a high-pressure homogenizer comprising a channel module comprising a microchannel through which an object for homogenization passes, wherein the microchannel is provided with a first flow channel and a second flow channel sequentially arranged along the direction through which the object passes, the first flow channel is provided with a plurality of first baffles disposed so as to partition the microchannel into a plurality of spaces, the second flow channel is provided with a plurality of second baffles disposed so as to partition the microchannel into a plurality of spaces, and at least one of the first baffles is provided to be positioned between two adjacent second baffles.

Abstract: A semiconductor device includes a substrate having a cell area and a peripheral area, transistors in the peripheral area over the substrate, a lower interlayer insulating layer between the transistors, interconnections and a first spacer layer over the transistors and the lower interlayer insulating layer, an upper interlayer insulating layer over the interconnections and the first spacer layer. The first spacer layer is disposed between the interconnections, The first spacer layer includes a first lower spacer layer and a first upper spacer layer over the first lower spacer layer. The first lower spacer layer and the first upper spacer layer include silicon, boron, and nitrogen. A boron concentration of the first lower spacer layer is different from a boron concentration of the first upper spacer layer.

Abstract: The present disclosure relates to a method for preparation of 1,4-cyclohexanedimethanol. According to the present disclosure, two step reduction reactions are conducted using terephthalic acid as starting material, and an isomerization process for increasing the rate of trans isomers of CHDA is introduced therebetween, thereby providing a method capable of stably preparing CHDM with high rate of trans isomers.

Abstract: This invention relates to a method for preparing 1,4-cyclohexanedimethanol(CHDM), more specifically to a method for preparing 1,4-cyclohexanedimethanol having a high rate of trans isomers without an isomerization reaction step.

Abstract: This invention relates to a method for preparing 1,4-cyclohexanedimethanol (CHDM), more specifically to a method for preparing 1,4-cyclohexanedimethanol having a high rate of trans isomers without an isomerization reaction step, wherein two-step hydrogenation reactions and a purification step are conducted using terephthalic acid as starting material.

Abstract: This invention relates to a method for preparing 1,4-cyclohexane dicarboxylic acid (CHDA). More specifically, this invention relates to a method for preparing 1,4-cyclohexane dicarboxylic acid having a high rate of trans isomers, without an isomerization reaction step.

Abstract: A reactor for nanoparticle production comprising a main chamber including a first nozzle to which raw material gas is supplied, a lens housing connected to the main chamber in a fluidly movable manner and including a second nozzle for supplying flushing gas to the lens housing, a lens mounted on the lens housing, a light source for irradiating a laser, which passes through the lens to reach the raw material gas in the main chamber, and a hood for discharging nanoparticles generated in the main chamber. A cross-sectional area of at least a part of the lens housing decreases along a direction facing the main chamber.